OBJECTIVE: To establish the maximum tolerated dose of Clostridium novyi-NT spores in tumor-bearing dogs and evaluate spore germination within tumors and tumor response. ANIMALS: 6 client-owned dogs. PROCEDURES: A standard dose-escalation study was planned, with maximum tolerated dose defined as the highest dose at which 0 or 1 of 6 dogs had dose-limiting toxicoses (DLT). Dogs received 1 dose of C. novyi-NT spores i.v.. Toxicoses were graded and interventions performed according to specific guidelines. Grade 3 or higher toxicosis or any toxicosis combination that substantially affected patient status was considered DLT. Clinical response was measured by use of response evaluation criteria in solid tumors at 28 days. RESULTS: The first 2 dogs had DLT. The dose was decreased. Two of the next 4 dogs had DLT; therefore, dose administration was stopped because the study endpoint had been reached. The most common toxicosis was fever (n = 6 dogs). Two dogs developed abscesses (1 within a nasal carcinoma and 1 splenic abscess) attributable to C. novyi-NT infection; both required surgical intervention. Clostridium novyi-NT was cultured from 1 of 6 tumors. Five dogs were available for response assessment (4 had stable disease; 1 had progressive disease). CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that C. novyi-NT can germinate within tumors of dogs. Toxicosis, although common and sometimes severe, was manageable with treatment. Further studies in dogs with superficial tumors may allow for continued dose escalation and provide information for use in clinical trials in veterinary and human oncology.
OBJECTIVE: To establish the maximum tolerated dose of Clostridium novyi-NT spores in tumor-bearing dogs and evaluate spore germination within tumors and tumor response. ANIMALS: 6 client-owned dogs. PROCEDURES: A standard dose-escalation study was planned, with maximum tolerated dose defined as the highest dose at which 0 or 1 of 6 dogs had dose-limiting toxicoses (DLT). Dogs received 1 dose of C. novyi-NT spores i.v.. Toxicoses were graded and interventions performed according to specific guidelines. Grade 3 or higher toxicosis or any toxicosis combination that substantially affected patient status was considered DLT. Clinical response was measured by use of response evaluation criteria in solid tumors at 28 days. RESULTS: The first 2 dogs had DLT. The dose was decreased. Two of the next 4 dogs had DLT; therefore, dose administration was stopped because the study endpoint had been reached. The most common toxicosis was fever (n = 6 dogs). Two dogs developed abscesses (1 within a nasal carcinoma and 1 splenic abscess) attributable to C. novyi-NT infection; both required surgical intervention. Clostridium novyi-NT was cultured from 1 of 6 tumors. Five dogs were available for response assessment (4 had stable disease; 1 had progressive disease). CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that C. novyi-NT can germinate within tumors of dogs. Toxicosis, although common and sometimes severe, was manageable with treatment. Further studies in dogs with superficial tumors may allow for continued dose escalation and provide information for use in clinical trials in veterinary and human oncology.
Authors: Luis A Diaz; Ian Cheong; Catherine A Foss; Xiaosong Zhang; Brock A Peters; Nishant Agrawal; Chetan Bettegowda; Baktiar Karim; Guosheng Liu; Khalid Khan; Xin Huang; Manu Kohli; Long H Dang; Paul Hwang; Ahava Vogelstein; Elizabeth Garrett-Mayer; Barry Kobrin; Martin Pomper; Shibin Zhou; Kenneth W Kinzler; Bert Vogelstein; David L Huso Journal: Toxicol Sci Date: 2005-09-14 Impact factor: 4.849
Authors: Nicholas J Roberts; Linping Zhang; Filip Janku; Amanda Collins; Ren-Yuan Bai; Verena Staedtke; Saurabh Saha; Shibin Zhou; Anthony W Rusk; David Tung; Maria Miller; Jeffrey Roix; Kristen V Khanna; Ravi Murthy; Robert S Benjamin; Thorunn Helgason; Ariel D Szvalb; Justin E Bird; Sinchita Roy-Chowdhuri; Halle H Zhang; Yuan Qiao; Baktiar Karim; Jennifer McDaniel; Amanda Elpiner; Alexandra Sahora; Joshua Lachowicz; Brenda Phillips; Avenelle Turner; Mary K Klein; Gerald Post; Luis A Diaz; Gregory J Riggins; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Chetan Bettegowda; David L Huso; Mary Varterasian Journal: Sci Transl Med Date: 2014-08-13 Impact factor: 17.956
Authors: Michael Frahm; Sebastian Felgner; Dino Kocijancic; Manfred Rohde; Michael Hensel; Roy Curtiss; Marc Erhardt; Siegfried Weiss Journal: MBio Date: 2015-04-14 Impact factor: 7.867